Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital One Financial

Equities research analysts at Capital One Financial initiated coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $6.00 price target on the biotechnology company’s stock. Capital One Financial‘s price target indicates a potential upside of 131.66% from the stock’s previous close.

A number of other research analysts have also issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a research note on Thursday, April 11th. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th.

Heron Therapeutics Stock Down 1.9 %

Shares of HRTX opened at $2.59 on Tuesday. The company has a 50 day moving average of $2.75 and a two-hundred day moving average of $1.94. Heron Therapeutics has a twelve month low of $0.50 and a twelve month high of $3.22. The company has a market cap of $389.35 million, a price-to-earnings ratio of -3.01 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.08. The business had revenue of $34.23 million for the quarter, compared to analysts’ expectations of $30.98 million. On average, sell-side analysts expect that Heron Therapeutics will post -0.22 EPS for the current year.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Victory Capital Management Inc. grew its position in Heron Therapeutics by 30.2% during the 4th quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 4,617 shares during the period. ACT Advisors LLC. purchased a new position in shares of Heron Therapeutics during the 4th quarter valued at about $38,000. Dakota Wealth Management purchased a new stake in shares of Heron Therapeutics in the third quarter worth about $55,000. Finally, Diversified Trust Co acquired a new stake in Heron Therapeutics during the first quarter worth about $66,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.